Skip to content
Open access

Real-world effectiveness and safety of Ocrelizumab in a gulf multiple sclerosis cohort: extension of the Q-OCRE study to 451 patients.

Oct 2026 · Multiple Sclerosis and Related Disorders · Vol 115, pp. 107971 · 0 citations · 25 references
Medicine

TL;DR

Ocrelizumab showed robust effectiveness and a favorable safety profile in this Gulf cohort, with disability trajectories dissociating by phenotype, with disability trajectories dissociating by phenotype.

Abstract

Real-world evidence on ocrelizumab in multiple sclerosis (MS) from the Middle East and North Africa (MENA) is limited. We extended our original Q-OCRE cohort (n = 60) to evaluate effectiveness and safety in an ethnically diverse Gulf population. In a single-center retrospective cohort of all patients starting ocrelizumab at Hamad General Hospital, Doha, Qatar (October 2017-May 2025), the primary outcome was No Evidence of Disease Activity (NEDA-3) at Year 1; secondary outcomes were annualized relapse rate (ARR), Expanded Disability Status Scale (EDSS) trajectory, 24-week confirmed disability worsening (CDW), persistence, and safety. A total of 451 patients were included (86.7% RRMS, 7.1% SPMS, 6.2% PPMS; 57.6% female; mean age 34.3 years; median follow-up 18.1 months; 696 person-years). The cohort was mildly affected at initiation (median EDSS 1.0; 42% with no relapse in the prior 2 years). ARR fell from 0.381 to 0.046, an 87% reduction (IRR 0.13, 95% CI 0.07-0.22, p < 0.001), preserved in patients meeting trial-like activity criteria (IRR 0.09). The EDSS slope was -0.04 points/year (p = 0.03) with a phenotype-by-time interaction (p < 0.001): RRMS improved while progressive forms worsened. NEDA-3 was 59.0% at Year 1 and 61.7% at Year 2. 24-week CDW reached 8.9% at 36 months, progressive phenotype being the only independent predictor (HR 5.02). Persistence was 90.7% at 36 months. Infusion-related reactions occurred in 18.4%, adjudicated opportunistic infections in 1.0%, IgG below 7 g/L in 6.9%, and incident malignancy in 0.4%, with no deaths and no progressive multifocal leukoencephalopathy. Ocrelizumab showed robust effectiveness and a favorable safety profile in this Gulf cohort, with disability trajectories dissociating by phenotype.

Read PDF

Similar papers

Review Open access Oct 2026

Real-world observational study of ocrelizumab and ofatumumab in patients with multiple sclerosis in Brazil

Background: Anti-CD20 therapies are widely used in multiple sclerosis (MS), and real-world data may complement findings from clinical trials. Objective: The objective is to evaluate the effectiveness and safety of ofatumumab and ocrelizumab in patients with MS in a real-world setting. Methods: This was a single-center,...

Carolina Mibielli de Souza, Samara Abdo El Hakim Kadri, C. Disserol et al. · 0 citations
Open access Sep 2026

Real-world effectiveness and safety of secukinumab in giant cell arteritis: an Italian multicentre cohort study.

In this multicentre real-world cohort of patients with GCA, including those with relapsing disease and previous biologic exposure, secukinumab was associated with high observed remission rates, progressive GC dose reduction and increasing GC-free remission.

L. Iorio, F. Davanzo, C. Ricordi et al. · 0 citations
Open access Oct 2026

Real-World Safety and Effectiveness of Cladribine Tablets in Older (≥ 50 Years) Patients with Relapsing Multiple Sclerosis: Results from the “Aging” Study—A Multicenter, Single-Arm, Phase 4 Observational Study

Older patients with relapsing multiple sclerosis (PwRMS) are often underrepresented in clinical trials, limiting evidence on the safety and effectiveness of disease-modifying therapies. This study characterized the safety and effectiveness of short-course treatment with cladribine tablets (CladT) over 24 months in PwRM...

J. Katz, Amy Gutierrez, L. Goldstick et al. · 0 citations
Open access Nov 2026

Real-world effectiveness and safety of risankizumab in multirefractory Crohn’s disease: A multicenter AIRIS-Crohn registry analysis

BACKGROUND Many patients with Crohn’s disease (CD) remain uncontrolled despite multiple biologic therapies. Risankizumab, a selective interleukin-23p19 inhibitor, has shown efficacy in clinical trials, but real-world data in multirefractory CD are still scarce. AIM To evaluate the 12-month effectiveness and safety o...

A. Caballero-Mateos, T. Valdés Delgado, R. Olmedo Martín et al. · 1 citation
Open access Oct 2026

Long-term clinical, radiological, and safety outcomes during fingolimod treatment in relapsing–remitting multiple sclerosis: a real-world cohort from Saudi Arabia

Fingolimod, a sphingosine-1-phosphate receptor modulator, has demonstrated robust efficacy in relapsing–remitting multiple sclerosis (RRMS). However, real-world long-term data from Middle Eastern populations remain limited. This study aimed to describe long-term clinical, radiological, laboratory, and cardiac outcomes...

Naila Aljahdali, A. Dahshan, Sherif R. Fayed et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.